Is Vasomotion in Cerebral Arteries Impaired in Alzheimer's Disease?

Luigi Yuri Di Marco1, Eszter Farkas2, Chris Martin3

  • 1Centre for Computational Imaging and Simulation Technologies in Biomedicine (CISTIB), Department of Electronic and Electrical Engineering, University of Sheffield, Sheffield, UK.

Insights

Impaired cerebral vasomotion, the rhythmic change in brain artery diameter, may worsen Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA). This dysfunction contributes to reduced blood flow and amyloid-beta accumulation.

Area of Science:

  • Neuroscience
  • Cerebrovascular Medicine
  • Pathophysiology

Background:

  • Alzheimer's disease (AD) pathogenesis involves vascular factors like cerebral hypoperfusion and blood-brain barrier dysfunction.
  • Cerebral amyloid angiopathy (CAA), common in AD, involves amyloid-beta (Aβ) deposition in cerebral vessels, compromising vascular integrity and circulation.
  • Vasomotion, the rhythmic modulation of arterial diameter, is crucial for regulating cerebral perfusion and oxygen delivery.

Purpose of the Study:

  • To review the literature on cerebral vasomotion in the context of AD and CAA.
  • To hypothesize the mechanisms by which impaired vasomotion contributes to AD/CAA pathogenesis.
  • To explore the role of vasomotion in Aβ clearance and cerebrovascular regulation.

Main Methods:

  • Literature review of studies on vasomotion, AD, and CAA.
  • Analysis of the impact of Aβ, oxidative stress, and cholinergic deficits on vascular tone and vasomotion.
  • Hypothesizing pathways linking impaired vasomotion to hypoperfusion and Aβ accumulation.

Main Results:

  • Impaired vasomotion is observed in conditions like hypoperfusion and hypoxia.
  • Aβ and oxidative stress dysregulate vascular tone, potentially impairing vasomotion.
  • Cholinergic deficits may further depress cerebrovascular reactivity and vasomotion, exacerbating hypoperfusion and Aβ buildup.

Conclusions:

  • Impaired cerebral vasomotion is a potential contributing factor to Alzheimer's disease and cerebral amyloid angiopathy.
  • Dysfunctional vasomotion may exacerbate hypoperfusion, promote Aβ accumulation, and worsen oxidative stress.
  • Further research is needed to elucidate the precise role and therapeutic potential of targeting cerebral vasomotion in AD/CAA.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
730